Superbugs are spreading as India faces gaps in drug supply, access to treatment
While antibiotics are being overused in some places, leading to the rise of deadly superbugs, in other parts of the world, people are dying because they can't access these life-saving drugs at all.A study, published in The Lancet Infectious Diseases, was led by the Global Antibiotic Research and Development Partnership (GARDP), a non-profit that works to improve access to antibiotics, looked at nearly 1.5 million cases of infections caused by carbapenem-resistant Gram-negative (CRGN) bacteria across eight low- and middle-income countries, including India, Brazil, and South Africa.advertisementCRGN bacteria are dangerous because they are resistant to "last-line" antibiotics. These are medicines that are used when all others fail.
Yet, the study found that only 6.9% of patients in these countries received the right treatment.INDIA CARRIES THE HEAVIEST BURDENIndia had the largest number of cases among all countries studied. It also procured 80% of the full antibiotic courses examined. But despite this, only 7.8% of people with CRGN infections received the proper treatment.This points to a gap between drug supply and actual access to treatment.A full course of antibiotics means the complete number of doses a patient must take to fully fight off an infection.
The study found that only 6.9% of patients in 8 countries, including India, received the right treatment. ()
advertisementMissing out on even a part of this treatment makes it less effective and more dangerous in the long run.These drug-resistant bacteria are commonly found in water, food, the environment, and even in our own bodies. They can cause serious infections like urinary tract infections (UTIs), pneumonia, and food poisoning.Newborn babies, elderly people, and hospital patients are especially at risk, particularly those in intensive care units (ICUs).CRGN infections are tough to treat because the bacteria no longer responds to some of the most powerful antibiotics we have. This is where the crisis deepens: in places where these infections are rising, the drugs needed to treat them are either missing or too expensive.THE ACCESS CRISISFor years, the focus has been on the overuse of antibiotics.According to Dr. Jennifer Cohn, GARDP's Global Access Director, the reality is that many people in low- and middle-income countries with deadly drug-resistant infections are "dying because they can't get the antibiotics they need," she was quoted by BBC.The study looked at eight different intravenous antibiotics that are active against these resistant bacteria.
Bacterial infections are tough to treat because the bacteriano longer responds to some of the most powerful antibiotics we have. ()
Tigecycline, one of the drugs in the study, was the most widely used. But even then, only about 1 lakh full courses were available across all eight countries, far fewer than the 1.5 million people who needed them.WHY ARE PATIENTS MISSING OUT?As per the study, there are many reasons why patients don't receive the right treatment.This could be because they aren't reaching the right hospital or clinic, not getting an accurate diagnosis, not able to access the correct antibiotics or there's a high cost of newer drugs.Many of these antibiotics are simply too expensive for the average patient in countries like India. Without better policies, price regulation, and access programs, millions will continue to suffer or die needlessly.SMARTER POLICIESThe experts said that two things are needed urgently: stronger rules to prevent misuse of antibiotics and better systems to make them affordable and available to those who truly need them.But access alone isn't enough. The world is also facing a shrinking pipeline of new antibiotics.advertisementWith fewer companies investing in antibiotic research, the options for treating future infections are limited.India has one of the highest burdens of antimicrobial resistance (AMR) in the world. But researchers say the country also holds great potential to lead the global fight against drug-resistant infections.
India has one of the highest burdens of antimicrobial resistance (AMR) in the world. ()
India's strong pharmaceutical sector is already leading efforts in antibiotic innovation. From developing new drugs to improving diagnostics, the country has a head start.Experts suggest that India can further improve by gathering local data. This would help identify what's needed, where the gaps are, and how to fix them. Some states are already trying new models.For instance, Kerala is using a "hub-and-spoke" system where smaller clinics get support from larger hospitals in treating complex infections.Another solution is pooled procurement, where hospitals or states buy drugs together in bulk, reducing costs. This has worked for cancer medicines and could be tried for antibiotics too.In the end, the battle against superbugs is not just about using antibiotics wisely, it's also about making sure they're within everyone's reach.Trending Reel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
8 hours ago
- Hans India
Imported seafood increasing resistance to colistin, a potent antibiotic: Study
A team of US researchers on Sunday said it has identified a way that colistin (a potent, last-resort antibiotic) resistance genes are spreading via imported seafood. Colistin is used only to treat people with dangerous, life-threatening bacterial infections that have developed resistance to other drugs. But it's not foolproof. Worldwide, resistance to colistin is spreading, further diminishing treatment options and putting infected people at higher risk. Researchers from the University of Georgia recently identified a way that colistin resistance genes are spreading. In a new study, microbiologist Issmat Kassem, and his group have reported the first isolation of colistin-resistance genes in bacteria found in imported shrimp and scallops, purchased from 8 food markets around Atlanta. 'Many people don't know that most seafood consumed in the U.S. is imported, Kassem said, including about 90 per cent of shrimp. Imported seafood is screened for contaminants but the process doesn't catch everything, especially antimicrobial resistance genes. 'The bacteria that were carrying colistin resistance genes are not normally screened.' Kassem and his group also found that some of the resistance genes are carried on plasmids — round bits of genetic material that can be transmitted from bacteria to bacteria. Antimicrobial resistant infections kill hundreds of thousands of people globally every year, and antimicrobial resistance is a rising public health menace. Colistin was first introduced in the 1950s to treat infections by pathogenic Gram-negative bacteria, but it takes a heavy toll on patients, including increased risk of damage to the nerves and kidneys. It was discontinued in the U.S. in the 1980s. However, Kassem noted, other countries continued to use it in agricultural settings, both to treat infections and to promote animal growth. Colistin was eventually reintroduced to human medicine because it was one of the few options available to treat certain bacterial infections. The World Health Organization categorises colistin as a high priority critically important antibiotic, which means it is an essential option for treating serious human infections. Researchers cautioned that the group identified 1 source of colistin resistance, but there could be other, and they're likely spreading.
The Hindu
9 hours ago
- The Hindu
All you need to know about : Gwada negative
In a groundbreaking announcement, France's national blood agency, the Établissement Français du Sang or French Blood Establishment (EFS), has identified a completely new blood group system, now officially recognised by the International Society of Blood Transfusion (ISBT). Named EMM-negative and colloquially dubbed 'Gwada negative' in reference to the Guadeloupean origin of the woman who carries it, this blood type is unlike any other. As of June 2025, only one person in the world is known to possess this blood type, making it the rarest ever recorded. What is Gwada Negative? Gwada negative is the informal name given to the newly classified EMM-negative blood group system, officially registered by ISBT as ISBT042. It is defined by the absence of the EMM antigen, which is normally found on red blood cells and is considered a high-incidence antigen. High-incidence antigens are present in nearly all humans, so the lack of one, as in this case, is extremely rare and medically significant. According to the ISBT, for a blood group to be considered a new system, it must fulfill several criteria: it should be genetically determined, inherited, identifiable via serological or molecular techniques, and have an associated antibody -- criteria that EMM-negative meets. The identification of the EMM-negative blood type adds to the previously known 47 blood group systems, making it the 48th globally recognised system in transfusion science. How was it discovered and by whom? The story began back in 2011, when a 54-year-old woman from Guadeloupe, who was living in Paris, underwent routine blood tests before surgery. During testing, scientists noticed an antibody that could not be identified by known blood group systems. At the time, the technology needed to analyse the anomaly wasn't fully developed. According to Thierry Peyrard, a medical biologist with the EFS who led the research, it wasn't until 2019 that researchers used high-throughput DNA sequencing -- also known as next-generation sequencing (NGS), a technology that enables the rapid sequencing of vast amounts of DNA or RNA in parallel, significantly increasing speed and efficiency compared to traditional methods -- to uncover the unique genetic mutation responsible for the absence of the EMM antigen. Their research was conducted over many years and after thorough validation and peer review, the ISBT officially recognised the discovery in June 2025 during its meeting in Milan. The woman's blood was found to possess a completely new serologic profile, confirming a novel and rare blood group system. Who has it and why is it so rare? As of now, the woman from Guadeloupe is the only known person in the world to possess this blood type. Her case is especially unique because she inherited the mutated gene from both her mother and her father, each of whom likely carried a single copy of the rare gene variant. This dual inheritance led to a complete lack of the EMM antigen in her red blood cells. According to Dr. Peyrard, this woman is 'compatible only with herself,' meaning that no currently identified donor could safely give her blood in the event of a transfusion. The rarity of her case is due to the extremely high prevalence of the EMM antigen in the human population; nearly everyone has it. When a person lacks such a high-frequency antigen, it places them in an extremely rare blood group category. Scientists now hope to identify others who might share the same genetic variant to better support patients with similar needs in the future. Why does it matter clinically? The discovery of Gwada negative is far more than a scientific curiosity -- it has important implications for transfusion medicine. Individuals who lack common red blood cell antigens like EMM can produce alloantibodies (antibodies produced by an individual in response to foreign antigens from another individual of the same species) against them. If such individuals receive blood containing the antigen they lack, their immune system may recognise it as foreign, potentially leading to dangerous transfusion reactions, including hemolysis --premature destruction or breakdown of red blood cells. In this patient's case, no donor blood containing the EMM antigen would be safe. According to the EFS and transfusion specialists, recognising rare blood groups like this one is crucial for ensuring safe transfusions and for guiding blood banks in identifying, cataloging, and preserving rare blood units. It also highlights the importance of building and maintaining international rare blood donor registries that can provide lifesaving support in critical situations. Specialists hightlight that the formal recognition of the EMM-negative, or 'Gwada negative,' blood type represents a critical advancement in haematology and transfusion medicine. This rare blood type broadens the scientific understanding of human immunohematological diversity and highlights the essential role of advanced genetic screening in ensuring safe and accurate blood matching, particularly in complex clinical and emergency settings.
India Today
4 days ago
- India Today
Lenacapavir becomes first FDA-approved HIV preventive drug: All about it
In a major breakthrough in the fight against HIV, the US Food and Drug Administration (FDA) has approved lenacapavir, under the brand name Yeztugo, a long-acting injectable drug developed by Gilead Sciences, as a preventive treatment for HIV. It has been in the making for over two for HIV prevention is not approved by any regulatory authority outside the US. There is currently no cure for HIV or makes Yeztugo the first and only HIV pre-exposure prophylaxis (PrEP) option in the United States that is required just twice a year. The injectable drug is approved for use in adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sexual trial data show over 99.9% of people who received Yeztugo remained HIV-negative during the study period, highlighting its strong potential to prevent HIV infections.'This is a historic day in the decades-long fight against HIV. Yeztugo only needs to be given twice a year and has shown remarkable results. It could transform HIV prevention,' said Daniel O'Day, CEO of Gilead FOR HIV PREVENTIONThe first PrEP medication, also made by Gilead, was approved in 2012. But as of 2022, only about 1 in 3 people in the US who were eligible for PrEP were actually prescribed it, according to the Centers for Disease Control and Prevention (CDC).advertisementMany people, especially women, Black and Latino communities, and people in the US South, continue to face challenges such as stigma, lack of awareness, and difficulties in sticking to daily oral medications.'Yeztugo could be the transformative option we've been waiting for. A twice-yearly shot could help overcome key barriers like adherence and stigma,' said Dr. Carlos del Rio, Professor of Medicine at Emory YEZTUGO WORKSYeztugo contains lenacapavir, a unique antiretroviral that works by blocking HIV (Human Immunodeficiency Virus) at multiple stages of its life cycle, unlike most drugs that target just one. The injectable drug is approved for use in adults and adolescents weighing at least 35 kg who are at risk of acquiring HIV through sexual contact. () It is not a complete treatment for people who already have HIV, and people must be tested for HIV before starting the company has also highlighted certain safety warnings of the drug:People must be confirmed HIV-negative before starting or continuing Yeztugo. Taking it unknowingly while already infected with HIV can lead to drug-resistant strains of the side effects include injection site reactions, headache, and the drug stays in the body for up to 12 months, missed doses or improper use can increase the risk of infection and drug should not be used by individuals who are HIV-positive or whose status is IT'S GIVENYeztugo is given as a subcutaneous injection every six months, but starts with a loading dose that includes two injections and oral a patient misses a scheduled injection, temporary oral tablets may be taken weekly until injections TRIAL SUCCESSThe FDA approval is based on two large Phase 3 trials, led by researchers from Emory University and Grady Health 1 Trial: Conducted in cisgender women in sub-Saharan Africa, this trial showed zero HIV infections among the 2,134 people who received Yeztugo, demonstrating 100% effectiveness compared to daily oral PrEP (Truvada).PURPOSE 2 Trial: Involved cisgender men and gender-diverse people across various countries. Out of 2,179 participants, only two HIV infections were recorded in those on Yeztugo, showing 99.9% effectiveness. Yeztugo is given as a subcutaneous injection every six months, but starts with a loading dose that includestwo injections and oral tablets. () advertisementBoth trials found Yeztugo to be superior to daily oral PrEP and it was generally well-tolerated, with no new safety light of this breakthrough, the peer-reviewed journal Science named lenacapavir its 2024 "Breakthrough of the Year."MAKING IT WIDELY ACCESSIBLE IN THE USTo make Yeztugo widely accessible, Gilead is working with insurers and health systems to include the drug in insurance uninsured individuals, Gilead's assistance program will provide Yeztugo free of cost, based on EXPANSION PLANSGilead has already filed for regulatory approval in Australia, Brazil, Canada, South Africa, and submitted applications to the European Medicines company is also preparing applications in countries like Argentina, Mexico, and Peru, which rely on FDA approvals for their own of now, Yeztugo is only approved in the United States for HIV prevention. There is no cure for HIV or AIDS, but preventive tools like Yeztugo bring the world closer to controlling the this FDA approval, the drug can help those who have struggled with traditional prevention methods, making the prevention more manageable.
